Guardant Health Reports Strong Q1 2025 Growth

Guardant Health ( (GH) ) has released its Q1 earnings. Here is a breakdown of the information Guardant Health presented to its investors.

Guardant Health is a precision oncology company specializing in advanced blood and tissue tests, real-world data, and AI analytics to improve cancer care and therapy development. In the first quarter of 2025, Guardant Health reported a 21% increase in revenue, reaching $203.5 million, driven by strong performance across its oncology, screening, and biopharma segments. The company also raised its 2025 revenue guidance to $880 to $890 million, reflecting a growth of 19% to 20%. Key financial highlights include a 20% increase in oncology revenue to $150.6 million and a 21% growth in biopharma and data revenue to $45.4 million. The company achieved positive gross margins for its Reveal and Shield products, and its operating expenses rose due to commercial expansion and marketing efforts. Despite a net loss of $95.2 million, the company improved its net loss per share to $0.77 compared to the previous year. Looking ahead, Guardant Health anticipates continued revenue growth and aims to achieve free cash flow breakeven for its non-screening business by the end of 2025.